Reason for Discontinuing VEGF-Targeted Therapy Affects Outcomes of Second-Line Therapies in Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Discontinuing VEGF-Targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-Line Therapies in Metastatic Renal Cell Carcinoma
Clin Genitourin Cancer 2017 Jan 13;[EPub Ahead of Print], G De Velasco, W Xie, F Donskov, L Albiges, B Beuselinck, S Srinivas, N Agarwal, JL Lee, J Brugarolas, LA Wood, SY Rha, C Kollmannsberger, S North, R Kanesvaran, BI Rini, R Broom, H Yamamoto, MD Kaymakcalan, DY Heng, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.